- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00676039
Comparison of the Pharmacokinetics of Two Generic Antidepressants and Their Respective Brand Preparations
Examination of the Pharmacokinetic Properties of Two Generic Antidepressants and Their Respective Brand Preparations in Healthy Male Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Z7K4
- University of Ottawa, Institute of Mental Health Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy volunteers (absence of diseases: psychiatric, physical, neurological, metabolic,...)
Exclusion Criteria:
- Psychiatric disorder
- Hepatic disease
- Renal disease
- Gastrointestinal disease
- Hematological disease
- Smokers
- Physical and/or neurological disease
- Positive urine drug screen
- Abnormal blood pressure
- Abnormal urine/blood analysis (sodium, potassium, chloride, creatinine, urea, ALT, AST, total protein, glucose, and TSH)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Crossover Effexor / NOVO-Venlafaxine Examination of the bioequivalence of Effexor (Wyeth Pharmaceuticals) and NOVO-Venlafaxine (NOVOPHARM). Both drugs will be given at the dose of 75 mg/day (one capsule per day) for 4 consecutive days. A washout period (corresponding to 10 half-life of the active metabolite desmethylvenlafaxine) will be respected after receiving each medication. |
NOVO-Venlafaxine XR 75 mg (NOVOPHARM, Generic)
Effexor XR 75 mg (Wyeth Pharmaceuticals, Brand Name)
|
Active Comparator: 2
Crossover Celexa/Gen-citalopram Examination of the bioequivalence of Celexa (Lundbeck, Brand Name) and Gen-Citalopram (Genpharm, Generic). Both drugs will be given at the dose of 40 mg/day (one tablet per day) for 8 consecutive days. A washout period (corresponding to 10 half-life of citalopram) will be respected after receiving each medication. |
Gen-Citalopram 40 mg (Genpharm, Generic)
Celexa 40 mg (Lundbeck, Brand Name)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Blood levels of drugs and their metabolite (when appropriate) will be evaluated for both the generic and the brand name medication.
Time Frame: 1 month
|
1 month
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Franck Chenu, Ph.D., University of Ottawa Institute of Mental Health Research
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Antidepressive Agents, Second-Generation
- Serotonin and Noradrenaline Reuptake Inhibitors
- Citalopram
- Venlafaxine Hydrochloride
Other Study ID Numbers
- REB-2007024
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Venlafaxine
-
Xijing HospitalUnknown
-
Actavis Inc.Completed
-
ShireCompletedHealthyUnited States
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaCompletedSleeve Gastrectomy | Roux en Y Gastric BypassUnited States
-
Club rTMS et PsychiatrieWyeth is now a wholly owned subsidiary of Pfizer; Ministry of Health, FranceCompletedUnipolar DepressionFrance, Monaco
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Lund UniversityShireCompleted
-
University of California, Los AngelesWyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...RecruitingMajor Depressive Disorder | Bipolar Affective Disorder, Currently Depressed, ModerateItaly